1.
Rosa AR, Reinares M, Franco C, Comes M, Torrent C, Sanchez-Moreno J, Martínez-Arán A, Salamero M, Kapczinski F, Vieta E: Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord 2009;11:401–409.
2.
Martinez-Arán A, Vieta E, Colom F, Torrent C, Sanchez-Moreno J, Reinares M, Benabarre A, Goikolea JM, Bruge E, Daban C, Salamero M: Cognitive impairment in euthymic bipolar patients, implications for clinical and functional outcome. Bipolar Disord 2004;6:224–232.
3.
Balanzá-Martínez V, Tabarés-Seisdedos R, Selva-Vera G, Martínez-Arán A, Torrent C, Salazar-Faile J, Leal-Cercos C, Vieta E, Gomez-Beneito M: Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study. Psychother Psychosom 2005;74:113–119.
4.
Torres IJ, Boudreau VG, Yatham LN: Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand 2007;116(suppl 434):17–26.
5.
Mur M, Portella MJ, Martínez-Arán A, Pifarré J, Vieta E: Persistent neuropsychological deficit in euthymic bipolar patients: executive function as a core deficit. J Clin Psychiatry 2007;68:1078–1086.
6.
Wingo AP, Harvey PD, Baldessarini RJ: Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord 2009;11:113–125.
7.
Tohen M, Hennen J, Zarate CM Jr, Baldessarini RJ, Strakowski SM, Stoll AL, Faedda GL, Suppes T, Gebre-Medhin P, Cohen BM: Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000;157:220–228.
8.
Martínez-Arán A, Vieta E, Torrent C, Sanchez-Moreno J, Goikolea JM, Salamero M, Malhi GS, Gonzaléz-Pinto A, Daba C, Alvarez-Grandi S, Fountoulakis K, Kaprinis G, Tabarés-Seisdedos R, Ayuso-Mateos JL: Functional outcome in bipolar disorders: the role of clinical and cognitive factors. Bipolar Disord 2007;9:103–113.
9.
Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos JL: Functioning and disability in bipolar disorders: an extensive review. Psychother Psychosom 2009;78:285–297.
10.
Martino DJ, Marengo E, Igoa A, Scapola M, Ais ED, Perinot L, Strejilevich SE: Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1-year follow-up study. J Affect Disord 2009;116:37–42.
11.
Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J, Martinez-Aran A, Salazar-Fraile J, Selva-Vera G, Rubio C, Mata I, Gómez-Beneyto M, Vieta E: Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord 2008;109:286–299.
12.
Jaeger J, Vieta E: Functional outcome and disability in bipolar disorders: ongoing research and future directions. Bipolar Disord 2007;9:1–2.
13.
Jaeger J, Berns S, Loftus S, Gonzalez C, Zobor P: Neurocognitive test performance predicts functional recovery from acute exacerbation leading to hospitalization in bipolar disorder. Bipolar Disord 2007;9:93–102.
14.
Bonnín CM, Martínez-Arán A, Torrent C, Pacchiarotti I, Rosa AR, Franco C, Murru A, Sanchez-Moreno J, Vieta E: Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord 2010;121:156–160.
15.
Green MF: Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67:e12.
16.
Twamley EW, Jeste DV, Bellack AS: A review of cognitive training in schizophrenia. Schizophr Bull 2003;2:359–382.
17.
Zarate CA, Tohen M, Land M, Cavanagh S: Functional impairment and cognition in bipolar disorder. Psychiatr Q 2000;71:309–329.
18.
Solé B, Bonnin CM, Torrent C, Balanzá-Martínez V, Tabarés-Seisdedos R, Popovic D, Martínez-Arán A, Vieta E: Neurocognitive impairment and psychosocial functioning in bipolar II disorder. Acta Psychiatr Scand, in press.
19.
McGurk SR, Mueser KT, Pascaris A: Cognitive training and supported employment for persons with severe mental Illness: one-year results from a randomised controlled trial. Schizophr Bull 2005;31:898–909.
20.
Choi J, Medalia M: Factors associated with a positive response to cognitive remediation in a community psychiatric sample. Psychiatric Serv 2005;56:602–604.
21.
Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ: Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord 2010;12:364–375.
22.
Glahn DC, Barrett J, Bearden CE, Mintz J, Green MF, Monkul ES, Najt P, Soares JC, Velligan DI: Dissociable mechanisms for memory impairment in bipolar disorder and schizophrenia. Psychol Med 2006;36:1085–1095.
23.
Brissos S, Videira V, Kapczinski F: Cognitive performance and quality of life in bipolar disorder. Can J Psychiatry 2008;53:517–524.
24.
Rozenthal M, Laks J, Engelhardt E: Neuropsychological aspects of depression. Rev Psiquiatria Rio Grande Sul 2004;26:204–212.
25.
Burdick KE, Braga RJ, Goldberg JF, Malhotra AK: Cognitive dysfunction in bipolar disorder. Future place of pharmacotherapy. CNS Drugs 2007;21:971–981.
26.
Tufrey K, Coulston C: Cognitive remediation for bipolar disorder: adapting from models used in schizophrenia and acquired brain injury. Acta Neuropsiquiatr 2010;22:311–313.
27.
Martínez-Arán A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J, Benabarre A, Goikolea JM, Comes M, Salamero M: Cognitive functions across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004;161:262–270.
28.
Goodwin GM, Martínez-Arán A, Glahn DC, Vieta E: Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008;18:787–793.
29.
Leifker F R, Patterson T L, Bowie CR, Mausbach BT, Harvey PD: Psychometric properties of performance-based functional capacity: test-retest reliability, practice effects, and potential sensitivity to change. Schizophr Res 2010;119:246–252.
30.
Rocca C, Lafer B: Alterações neuropsicológicas no transtorno bipolar. Rev Bras Psiquiatr 2006;28:226–237.
31.
Schwalbe E, Medalia A: Cognitive dysfunction and competency restoration: using cognitive remediation to help restore the unrestorable. J Am Acad Psychiatry Law 2007;35:518–525.
32.
Medalia A, Dom H, Watras-Gans S: Treating problem-solving deficits on acute care psychiatric inpatient unit. Psychiatry Res 2000;97:79–88.
33.
McGurk SR, Schiano D, Mueser KT, Wolfe R: Implementation of the thinking skills for program in a psychosocial clubhouse. Psychiatr Rehabil J 2010;33:190–199.
34.
Deckersbach T, Nierenberg AA, Kessler R, Lund HG, Ametrano RM, Sachs G, Rauch SL, Dougherty D: Cognitive rehabilitation for bipolar disorders: an open trial for employed patients with residual depressive symptoms. CNS Neurosci Ther 2010;16:298–307.
35.
Daban C, Martinez-Aran A, Torrent C, Tabarés-Seisdedos, Balanzá-Martínez V, Salazar-Fraile, Selva-Vera G, Vieta E: Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychother Psychosom 2006;75:72–84.
36.
Barch DM: Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences. Curr Psychiatry Rep 2009;11:313–319.
37.
Solé B, Martínez-Arán A, Torrent C, Bonnin CM, Reinares M, Popovic D, Sánchez-Moreno J, Vieta E: Are bipolar II patients cognitively impaired? A systematic review. Psychol Med 2011;41:1791–1803.
38.
Müller D, Roder V: Integrated psychological therapy and integrated neurocognitive therapy; in Roder V, Medalia A (eds): Neurocognition and Social Cognition in Schizophrenia Patients. Basel, Karger, 2010, pp 118–144.
39.
Medalia S, Mambrino E: An overview of the neuropsychological and neurological approach to remediation; in Roder V, Medalia A (eds): Neurocognition and Social Cognition in Schizophrenia Patients. Basel, Karger, 2010, pp 104–117.
40.
Hogarty GE, Flesher S: Developmental theory for a cognitive enhancement therapy of schizophrenia. Schizophr Bull 1999;25:677–692.
41.
Hogarty GE, Flescher S, Ulrich R, Carter M, Green Wald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry L, Garrett A, Parepally H, Zoretich R: Cognitive enhancement therapy for schizophrenia. Arch Gen Psychiatry 2004;61:866–876.
42.
Martínez-Arán A, Torrent C, Solé B, Bonnín CM, Rosa AR, Sánchez-Moreno J, Vieta E: Functional remediation for bipolar disorder. Clin Pract Epidemiol Ment Health 2011;7:112–116.
© 2010 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2010 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.